display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer - HR positive
la/mBC - HR-positive - 1st line (L1)
lapatinib based treatment
lapatinib plus fulvestrant CALGB 40302
lapatinib plus letrozole EGF30008 ... EGF30008 ...

Study type: